Long-Term Liabilities: The sum of all non-current liabilities.
ImmunoPrecise Antibodies Ltd. (IPA) had Long-Term Liabilities of $8.07M for the most recently reported fiscal quarter, ending 2025-01-31.
| Income Statement Financials | |
$4.33M |
|
$-15.14M |
|
$2.01M |
|
$2.32M |
|
$6.56M |
|
$-2.23M |
|
$-15.02M |
|
$-17.26M |
|
$-2.36M |
|
$-15.14M |
|
$-15.14M |
|
$-15.14M |
|
$1.59M |
|
$-2.23M |
|
$-1.33M |
|
32.85M |
|
32.85M |
|
$-0.46 |
|
$-0.46 |
|
| Balance Sheet Financials | |
$14.59M |
|
$10.70M |
|
$17.44M |
|
$32.02M |
|
$6.28M |
|
$7.90M |
|
|
Long-Term Liabilities |
$8.07M |
$14.35M |
|
$17.67M |
|
$11.34M |
|
$17.67M |
|
45.77M |
|
| Cash Flow Statement Financials | |
$-3.71M |
|
$-0.31M |
|
$10.77M |
|
$2.49M |
|
$9.15M |
|
$6.65M |
|
$0.28M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.32 |
|
-- |
|
-- |
|
0.31 |
|
0.51 |
|
53.57% |
|
-51.62% |
|
-51.62% |
|
-- |
|
-398.88% |
|
-349.88% |
|
$-4.02M |
|
-- |
|
-- |
|
-- |
|
0.14 |
|
1.49 |
|
1.63 |
|
55.35 |
|
-85.66% |
|
-133.43% |
|
-47.26% |
|
-59.18% |
|
$0.39 |
|
$-0.12 |
|
$-0.11 |
|